Cynthia Miller
Family · Murfreesboro, TNNPI 1497790992
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $328,770 of the $383,602 with a category attached, or 85.7%. AbbVie accounts for 81.0% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2023 at $137,220 and has fallen 55.7% since, to $60,819 in 2025. Among family clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,002 payments — averaging $382.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$311K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$37K
- Vanda Pharmaceuticals Inc.$33K
- Alkermes, Inc.$572
- Axsome Therapeutics, Inc.$460
- Takeda Pharmaceuticals U.S.A., Inc.$305
- plus $2K from 16 others
What the payments were for
- Consulting fees$3,8751%
- Speaking & faculty fees$328,77086%
- Travel & lodging$38,44810%
- Food & beverage$12,5013%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 639 | $310,702 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 119 | $36,830 |
| Vanda Pharmaceuticals Inc. | 76 | $33,063 |
| Alkermes, Inc. | 31 | $572 |
| Axsome Therapeutics, Inc. | 17 | $460 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $305 |
| Otsuka America Pharmaceutical, Inc. | 15 | $281 |
| Lundbeck LLC | 15 | $268 |
| Teva Pharmaceuticals USA, Inc. | 13 | $236 |
| Johnson & Johnson | 12 | $217 |
| Neurocrine Biosciences, Inc. | 7 | $112 |
| Merck | 7 | $112 |
| Sunovion Pharmaceuticals Inc. | 9 | $92 |
| Idorsia Pharmaceuticals US Inc | 5 | $85 |
| Bausch Health US, LLC | 5 | $72 |
| Adlon Therapeutics L.p. | 4 | $57 |
| Eisai Inc. | 3 | $40 |
| Tris Pharma Inc | 2 | $37 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Tempus AI, Inc | 1 | $15 |
| Corium, LLC | 1 | $15 |
| Acadia Pharmaceuticals Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$383,602 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrintellixVortioxetine Hydrobromide | 20 | $10,075 |
| Lurasidone Hcl | 11 | $5,295 |
| Bupropion XlBupropion Hcl | 53 | $2,061 |
| Vilazodone Hcl | 11 | $1,700 |
| Aripiprazole | 17 | $1,671 |
| Fluoxetine Hcl | 19 | $453 |
| Quetiapine Fumarate | 38 | $363 |
| Risperidone | 11 | $301 |
| Trazodone Hcl | 37 | $224 |
| Eszopiclone | 11 | $220 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 11 | $200 |
| Sertraline Hcl | 17 | $129 |
| Hydroxyzine Pamoate | 13 | $120 |
| Alprazolam | 19 | $43 |
| Lorazepam | 12 | $17 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $305 | $10,07520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.
Other family in Murfreesboro
- Melanie McGheeMurfreesboro$48K
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
- Laura PorchCordova$148K
- Lori LankfordNashville$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.